CRISPR Therapies Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, CRISPR Therapies pipeline constitutes 25+ key companies continuously working towards developing 30+ CRISPR Therapies treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"CRISPR Therapies Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CRISPR Therapies Market.

The CRISPR Therapies Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the CRISPR Therapies Pipeline Report: https://www.delveinsight.com/report-store/crispr-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel CRISPR Therapies treatment therapies with a considerable amount of success over the years.
• CRISPR Therapies companies working in the treatment market are Beam Therapeutics, Tango Therapeutics, CRISPR therapeutics, Caribou Biosciences, Inc., KSQ Therapeutics, Intellia Therapeutics, Inc., Locus Biosciences, CRISPR Therapeutic, and others, are developing therapies for the CRISPR Therapies treatment
• Emerging CRISPR Therapies therapies such as - BEAM-301, TNG260, CTX 130, CB-010, KSQ-4279, NTLA-2002, LBP-EC01, CTX001, and others are expected to have a significant impact on the CRISPR Therapies market in the coming years.
• In August 2023, CRISPR Therapeutics initiated a single-dose, open-label study in participants with transfusion dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologousCRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) using CTX001
• In September 2023, Vertex Pharmaceuticals and CRISPR Therapeutics announced that Vertex has concluded discussions with the US Food and Drug Administration (FDA), and the FDA granted exagamglogene autotemcel (exa-cel) a rolling review for the potential treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
• In May 2022, CRISPR Therapeutics initiated a single-dose, open-label study in pediatric participants with TDT. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001)
• In June 2021, data from 22 patients with at least three months of follow-up after CTX001 infusion were presented and continued to build the profile of a potentially functional cure for patients with TDT and SCD, showing consistent and durable benefit with longer term data from a larger population of patients

CRISPR Therapies Overview
CRISPRs are specialized stretches of DNA. "CRISPR" stands for "clusters of regularly interspaced short palindromic repeats." It is a specialized region of DNA with two distinct characteristics: the presence of nucleotide repeats and spacers. Repeated sequences of nucleotides - the building blocks of DNA - are distributed throughout a CRISPR region. Spacers are bits of DNA that are interspersed among these repeated sequences. CRISPRs play a role in regulating bacterial immunity.

Get a Free Sample PDF Report to know more about CRISPR Therapies Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging CRISPR Therapies Drugs Under Different Phases of Clinical Development Include:
• BEAM-301: Beam Therapeutics
• TNG260: Tango Therapeutics
• CTX 130: CRISPR therapeutics
• CB-010: Caribou Biosciences, Inc.
• KSQ-4279: KSQ Therapeutics
• NTLA-2002: Intellia Therapeutics, Inc.
• LBP-EC01: Locus Biosciences
• CTX001: CRISPR Therapeutic

Route of Administration
CRISPR Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

CRISPR Therapies Pipeline Therapeutics Assessment
• CRISPR Therapies Assessment by Product Type
• CRISPR Therapies By Stage and Product Type
• CRISPR Therapies Assessment by Route of Administration
• CRISPR Therapies By Stage and Route of Administration
• CRISPR Therapies Assessment by Molecule Type
• CRISPR Therapies by Stage and Molecule Type

DelveInsight's CRISPR Therapies Report covers around 30+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further CRISPR Therapies product details are provided in the report. Download the CRISPR Therapies pipeline report to learn more about the emerging CRISPR Therapies therapies at:
https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the CRISPR Therapies Therapeutics Market include:
Key companies developing therapies for CRISPR Therapies are - Vertex Pharmaceuticals; Excision Biotherapeutic; CRISPR Therapeutics; Intellia Therapeutics; Editas Medicine; Thermo Fisher Scientific; Integrated DNA Technologies, Inc. (Danaher); GenScript Biotech Corporation; GeneCopoeia; Applied StemCell; Casebia Therapeutics; Modalis Therapeutics; Mustang Bio; Sarepta Therapeutics; Origene Technologies; ASC Therapeutics; Emendo Biotherapeutics; Precision Biosciences; Horizon Discovery; Synthego Corporation; Agilent Technologies; Evotec A.G; Beam Therapeutics; New England Biolabs; Novartis; Caribou Biosciences; Addgene among others.

CRISPR Therapies Pipeline Analysis:
The CRISPR Therapies pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of CRISPR Therapies with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CRISPR Therapies Treatment.
• CRISPR Therapies key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• CRISPR Therapies Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CRISPR Therapies market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about CRISPR Therapies drugs and therapies-
https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

CRISPR Therapies Pipeline Market Drivers
• New drugs are discovered employing the novel ways to treat diseases, CRISPR/Cas9 provides extensive opportunities for programmable gene editing, are some of the important factors that are fueling the CRISPR Therapies Market.

CRISPR Therapies Pipeline Market Barriers
• However, unwanted immune responses, off-target effects, CRISPR has tangible progress for localized administration and other factors are creating obstacles in the CRISPR Therapies Market growth

Scope of CRISPR Therapies Pipeline Drug Insight
• Coverage: Global
• Key CRISPR Therapies Companies: , and others
• Key CRISPR Therapies Therapies: BEAM-301, TNG260, CTX 130, CB-010, KSQ-4279, NTLA-2002, LBP-EC01, CTX001, and others
• CRISPR Therapies Therapeutic Assessment: CRISPR Therapies current marketed and CRISPR Therapies emerging therapies
• CRISPR Therapies Market Dynamics: CRISPR Therapies market drivers and CRISPR Therapies market barriers

Request for Sample PDF Report for CRISPR Therapies Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 CRISPR Therapies Report Introduction
2 CRISPR Therapies Executive Summary
3 CRISPR Therapies Overview
4 CRISPR Therapies- Analytical Perspective In-depth Commercial Assessment
5 CRISPR Therapies Pipeline Therapeutics
6 CRISPR Therapies Late Stage Products (Phase II/III)
7 CRISPR Therapies Mid Stage Products (Phase II)
8 CRISPR Therapies Early Stage Products (Phase I)
9 CRISPR Therapies Preclinical Stage Products
10 CRISPR Therapies Therapeutics Assessment
11 CRISPR Therapies Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 CRISPR Therapies Key Companies
14 CRISPR Therapies Key Products
15 CRISPR Therapies Unmet Needs
16 CRISPR Therapies Market Drivers and Barriers
17 CRISPR Therapies Future Perspectives and Conclusion
18 CRISPR Therapies Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Related Reports:
CRISPR Therapies Epidemiology https://www.delveinsight.com/report-store/crispr-therapies-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'CRISPR Therapies Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.